Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No association of IL-12p40 pro1.1 polymorphism with juvenile idiopathic arthritis.
Eberhardt CS, Haas JP, Girschick H, Schwarz T, Morbach H, Rösen-Wolff A, Foell D, Dannecker G, Schepp C, Ganser G, Honke N, Eggermann T, Müller-Berghaus J, Wagner N, Ohl K, Tenbrock K. Eberhardt CS, et al. Pediatr Rheumatol Online J. 2015 Dec 15;13:61. doi: 10.1186/s12969-015-0059-z. Pediatr Rheumatol Online J. 2015. PMID: 26667304 Free PMC article.
Challenges and issues of SARS-CoV-2 pool testing.
Eberhardt JN, Breuckmann NP, Eberhardt CS. Eberhardt JN, et al. Lancet Infect Dis. 2020 Nov;20(11):1233-1234. doi: 10.1016/S1473-3099(20)30467-9. Epub 2020 Jul 14. Lancet Infect Dis. 2020. PMID: 32679088 Free PMC article. No abstract available.
Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.
L'Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, Guessous I, Eberhardt CS, Huttner A, Posfay-Barbe KM, Yerly S, Siegrist CA, Kaiser L, Vuilleumier N. L'Huillier AG, et al. Eur J Clin Invest. 2022 Oct;52(10):e13818. doi: 10.1111/eci.13818. Epub 2022 Jun 2. Eur J Clin Invest. 2022. PMID: 35598178 Free PMC article.
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, Goldstein R, Grifoni A, Sette A, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Madelon N, et al. JAMA Neurol. 2022 Apr 1;79(4):399-404. doi: 10.1001/jamaneurol.2022.0245. JAMA Neurol. 2022. PMID: 35212717 Free PMC article.
156 results